1 December 2024 false Taxfiler 2024.6 12296485 business:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 12296485 2024-11-30 12296485 2024-12-01 2025-11-30 12296485 business:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 12296485 business:AbridgedAccounts 2024-12-01 2025-11-30 12296485 2025-11-30 12296485 2024-11-30 12296485 core:WithinOneYear 2025-11-30 12296485 core:WithinOneYear 2024-11-30 12296485 core:ShareCapital core:PreviouslyStatedAmount 2025-11-30 12296485 core:ShareCapital core:PreviouslyStatedAmount 2024-11-30 12296485 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-11-30 12296485 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2024-11-30 12296485 core:PreviouslyStatedAmount 2025-11-30 12296485 core:PreviouslyStatedAmount 2024-11-30 12296485 business:SmallEntities 2024-12-01 2025-11-30 12296485 business:Director1 2024-12-01 2025-11-30 12296485 countries:EnglandWales 2024-12-01 2025-11-30 12296485 business:RegisteredOffice 2024-12-01 2025-11-30 12296485 core:ComputerEquipment 2024-12-01 2025-11-30 12296485 2023-12-01 2024-11-30 iso4217:GBP xbrli:pure
Company Registration No. 12296485 (England and Wales)
MN Pharma Ltd Unaudited accounts for the year ended 30 November 2025
MN Pharma Ltd Accountants' report
Accountants' report to the director of MN Pharma Ltd on the preparation of the unaudited statutory accounts for the year ended 30 November 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of MN Pharma Ltd for the year ended 30 November 2025 as set out on pages 3 - 4 from the company's accounting records and from information and explanations you have given us.
This report is made solely to the Board of Directors of MN Pharma Ltd, as a body, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for your approval the accounts of MN Pharma Ltd and state those matters that we have agreed to state to them, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than MN Pharma Ltd and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that MN Pharma Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of MN Pharma Ltd. You consider that MN Pharma Ltd is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of MN Pharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
Sigmatax 3 August 2026
- 2 -
MN Pharma Ltd Statement of financial position as at 30 November 2025
2025
2024
Notes
£
£
Fixed assets
Tangible assets
4
1,838
-
Current assets
Debtors
489
489
Cash at bank and in hand
21,375
4,789
21,864
5,278
Creditors: amounts falling due within one year
(21,619)
(7,545)
Net current assets/(liabilities)
245
(2,267)
Net assets/(liabilities)
2,083
(2,267)
Capital and reserves
Called up share capital
1
1
Profit and loss account
2,082
(2,268)
Shareholders' funds
2,083
(2,267)
For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 3 August 2026 and were signed on its behalf by
Mr Haseeb Mahmood Director Company Registration No. 12296485
- 3 -
MN Pharma Ltd Notes to the Accounts for the year ended 30 November 2025
1
Statutory information
MN Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 12296485. The registered office is 26 Thorn Drive, Bradford, BD9 6LR, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
25% on cost.
4
Tangible fixed assets
Total
£
Cost or valuation
At 1 December 2024
1,651
Additions
2,450
At 30 November 2025
4,101
Depreciation
At 1 December 2024
1,651
Charge for the year
612
At 30 November 2025
2,263
Net book value
At 30 November 2025
1,838
5
Average number of employees
During the year the average number of employees was 1 (2024: 1).
- 4 -